Table 1: Baseline characteristics of patients with COVID-19 in treatment (hydroxychloroquine and azithromycin combined) and control group (no hydroxychloroquine + azithromycin).
| Variables | Total (N = 208) | Treatment group (N = 150) | Control group (N = 58) | p-value |
| n (%) | n (%) | n (%) | ||
| Patient age group | ||||
| < 45 years | 67 (32.2) | 46 (30.7) | 21 (36.2) | 0.739 |
| 45-64 years | 94 (45.2) | 69 (46.0) | 25 (43.1) | |
| ≥ 65 years | 47 (22.6) | 35 (23.3) | 12 (20.7) | |
| Sex | ||||
| Female | 84 (40.4) | 63 (42.0) | 21 (36.2) | 0.445 |
| Male | 124 (59.6) | 87 (58.0) | 37 (63.8) | |
| Occupation | ||||
| Health professional | 25 (12.0) | 20 (13.3) | 5 (8.6) | 0.349 |
| Others occupation | 183 (88.0) | 130 (86.7) | 53 (91.4) | |
| Pre-existing medical condition | ||||
| Hypertension | 54 (26.0) | 45 (30.0) | 9 (15.5) | 0.033 |
| Diabetes | 27 (13.0) | 23 (15.3) | 4 (6.9) | 0.104 |
| Chronic lung disease | 20 (9.6) | 17 (11.3) | 3 (5.2) | 0.177 |
| Others | 51 (24.52) | 37 (24.7) | 14 (24.1) | 0.937 |
| Number of pre-existing conditions | ||||
| None | 107 (51.4) | 70 (46.7) | 37 (63.8) | 0.086 |
| 1 | 58 (27.9) | 46 (30.7) | 12 (20.7) | |
| ≥ 2 | 43 (20.7) | 34 (22.7) | 9 (15.5) | |
| Number of days from symptoms onset to admission* | 8 (6-12) | 8 (6-13) | 7 (4-10.5) | 0.076 |
| Clinical signs | ||||
| Cough | 122 (58.6) | 98 (65.3) | 24 (41.4) | 0.002 |
| Fever | 149 (71.6) | 112 (74.7) | 37 (63.8) | 0.119 |
| Dyspnoea | 57 (27.4) | 44 (29.3) | 13 (22.4) | 0.316 |
| Asthenia | 60 (28.9) | 45 (30.0) | 15 (25.9) | 0.555 |
| Clinical constants | ||||
| Temperature* | 37.0 (36.5-37.5) | 37.0 (36.5-37.5) | 37.2 (36.7-38.0) | 0.196 |
| Systolic blood pressure* | 131 (120-150) | 136 (120-151) | 130 (110-140) | 0.113 |
| Diastolic blood pressure* | 82 (74.5-90) | 82 (76-90) | 80 (70-90) | 0.653 |
| Oxygen saturation* | 95 (89-97) | 95 (90-97) | 95 (77-97) | 0.279 |
| Heart rate* | 97 (84-110) | 94 (83-105) | 102 (88-112) | 0.203 |
*Values presented are medians (inter-quartile ranges)